Flat revertant inducers, styryl diphenylamine derivatives, inhibit growth and metastasis of murine tumor cells in vivo

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 393-400

  Ohizumi, Iwao ^a   Tanemura, Mitsuru ^a   Tsunenari, Toshiaki ^a   Sato, Koh ^a   Kozono, Toshiro ^a   Kairo, Shin Ichi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

B16 melanoma; Flat revertant; M5076 reticulosarcoma; Styryl diphenylamine derivative; Tumor growth; Tumor metastasis

Indexed keywords

DIPHENYLAMINE DERIVATIVE; RX 465; RX 512; RX 549; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CONTROLLED STUDY; FIBROSARCOMA; LIVER METASTASIS; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RETICULOSARCOMA; REVERTANT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DIPHENYLAMINE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NIACIN; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0031043443     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Leonard RC and Soukop M: Anti-emetics and cancer chemotherapy. Br J Cancer 61: 349-350, 1990.
2. Smith IE and Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer. Br J Cancer 65: 787-793, 1992.
3. van Putten LM, Kram LK, van Dierendonck HH, Smink T and Fuzy M: Enhancement by drugs of metastatic lung nodule formation after intravenous tumor cell injection. Int J Cancer 75: 588-595, 1975.
4. Kerbel RS and Davies AJ: Facilitation of tumor progression by cancer therapy. Lancet 2: 977-978, 1982.
5. Nicolson GL and Custead SE: Effect of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 45: 331-336, 1985.
6. Frost P, Kerbel RS, Hunt B, Man S and Pathak S: Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5azacytidine or hydroxyurea. Cancer Res 47: 2690-2695, 1987.
7. George E, Sharom FJ and Ling V: Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21: 185-220, 1990.
8. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ and Kerbel RS: Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86: 975-982, 1994.
9. Ohizumi I, Tanemura M and Kaiho S: A novel styryl diphenylamine derivative reverts the transformed phenotype of human fibrosarcoma HT1080 cells. Br J Cancer 72: 1219-1223, 1995.
10. Sakai R, Ikeda I, Kitani H, Fujiki H, Takaku F, Rapp U, Sugimura T and Nagao M: Flat reversion by okadaic acid of raf and ret-II transformants. Pro Natl Acad Sci USA 86: 9946-9950, 1989.
11. Uehara Y, Murakami Y, Sugimoto Y and Mizuno S: Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A. Cancer Res 49: 780-785, 1989.
12. Umezawa K, Tanaka K, Hori T, Abe S, Sekizawa RandImoto M: Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells. FEBS Letters 279: 132-136, 1991.
13. Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K and Nishimura S: Isolation of genes specifically expressed in flat revertant cells derived from activated rastransformed NIH3T3 cells by treatment with azatyrosine. Proc Natl Acad Sci USA 89: 4879-4883, 1992.
14. Kyprianou N and Taylor-Papadimitriou J: Isolation of azatyrosineinduced revertants from ras-transformed human mammary epithelial cells. Oncogene 7: 57-63, 1992.
15. Sugita K, Koizumi K and Yoshida H: Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res 52: 168-172, 1992.
16. Sugita K, Yoshida H, Matsumoto M and Matsutani S: A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene. Biochem Biophys Res Comm 182: 379-387, 1992.
17. 2. Cancer Res 51: 903-906, 1991.